Adalimumab desensitization after anaphylactic reaction

Quercia, O; Emiliani, F; Foschi, Francesco Giuseppe; Stefanini, Giuseppe Francesco

doi:10.1016/j.anai.2011.03.014

Cited by 31 publications

(16 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Certain patients can manifest with nausea, chills, fever, and malaise [7,25,26]. For trastuzumab, typical first-time infusion reactions include chills and/or fever and occur in approximately 40 % of patients [27].…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%

Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies

Bonamichi-Santos

Castells

2016

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Due to the increase in utilization of chemotherapies and antibodies, drug hypersensitivity reactions have increased dramatically worldwide, preventing the use of first-line therapies and impacting patients' survival and quality of life. Some of the more frequently used medications in cancer include taxanes for ovarian, lung, breast, and prostate cancers. Monoclonal antibodies are used in the treatment of neoplastic, autoimmune, and inflammatory diseases, and their clinical applications are becoming broader. Monoclonal antibody targets include CD20, HER-2, EGFR, IL-6 receptor, TNF-α, CD30, VEGF-A, IgE, and more, and examples of immunemediated and inflammatory diseases that respond to monoclonal antibodies include rheumatoid arthritis, Crohn's disease, ulcerative colitis, juvenile idiopathic arthritis, psoriasis and psoriatic arthritis, Wegener's granulomatosis, microscopic polyangiitis, ankylosing spondylitis, plaque psoriasis, and asthma. Neoplastic diseases include non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and colorectal, breast, gastric, and lung cancer. The clinical presentation of drug hypersensitivity reactions ranges from mild cutaneous reactions to lifethreatening symptoms including anaphylaxis. Rapid drug desensitization (RDD) has become a groundbreaking approach to the management of immediate drug hypersensitivity reactions IgE and non-IgE mediated. It is the only effective procedure that enables sensitized patients to receive the full treatment dose safely, thus representing an important advance in the patients' treatment and prognosis. The aim of this review is to provide an update on hypersensitivity reactions to commonly used monoclonal and taxanes, their clinical presentations, diagnosis, and the use of RDD for their management.

show abstract

Section: Monoclonal Antibodiesmentioning

confidence: 99%

Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies

Bonamichi-Santos

Castells

2016

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

show abstract

“…Immune-mediated adverse reactions to etanercept and adalimumab reported in the literature include injection site reactions (ISRs) and immediate systemic hypersensitivity reactions such as pruritus, urticaria, angioedema, and anaphylaxis. [1][2][3][4] ISRs are thought to be T lymphocyte-mediated delayed type IV hypersensitivity reactions, which may preclude subsequent medication administration. 5,6 Rapid drug desensitization protocols have been developed for the delivery of a variety of parenteral chemotherapeutic agents, including monoclonal antibodies, to sensitized patients.…”

Section: To the Editormentioning

confidence: 99%

Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients

Bavbek

Ataman

Akıncı

et al. 2015

The Journal of Allergy and Clinical Immunology: In Practice

View full text Add to dashboard Cite

“…Urticaria, angioedema and other skin reactions to adalimumab have been reported rarely [2–7]. Hitherto, there are few published case reports regarding adalimumab hypersensitivity and a successful desensitization protocol [2, 8]. Here we describe a case of a systemic hypersensitivity reaction to adalimumab and successful desensitization.…”

Section: Introductionmentioning

confidence: 92%

Desensitization to Adalimumab: An Example of Repeated Desensitization to a Biological Agent

Demirel

Kartal

Güleç

et al. 2015

Drug Saf - Case Rep

View full text Add to dashboard Cite

Biological agents seem to have been more effective than classic immunosuppressive drugs; however, the adverse events including the hypersensitivity reactions are the main drawbacks of these drugs. We report a 35-year-old man who was treated with adalimumab for ankylosing spondylitis, had a local reaction on the injection site, and generalized itching with rash at the 62nd dose and repeated desensitizations to him with adalimumab. One month after the reaction, skin prick test was performed with a commercial preparation of adalimumab. The skin prick test result was determined positive comparing to positive and negative controls. Because of insufficient responses to other drugs, adalimumab desensitization was performed and the whole process was completed without any reaction. Six months later the patient gave up therapy because of a new reaction which was caused by a possible viral infection. Desensitization was repeated successfully 3 months later. Because there are few cases in the literature about adalimumab desensitization process, there is no standard desensitization protocol for the adalimumab allergy yet. Therefore, we suggest that our case report may contribute to the formation of a standardized desensitization protocol in adalimumab hypersensitivity.

show abstract

Adalimumab desensitization after anaphylactic reaction

Cited by 31 publications

References 6 publications

Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies

Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies

Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients

Desensitization to Adalimumab: An Example of Repeated Desensitization to a Biological Agent

Contact Info

Product

Resources

About